Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 2

Biosimilar tumour necrosis factor (TNF)-α inhibitors have similar efficacy and safety profiles to their branded equivalents, the authors of a systematic review conclude

By looking at 19 studies involving seven biosimilars for etanercept, infliximab and adalimumab, researchers concluded that the treatments have similar efficacy to their branded equivalents

Source  Martin Shields / Alamy Stock Photo